Pharmacy Times Continuing Education™ Presents a Live Broadcast on Chronic Lymphocytic Leukemia on September 18, 2018

CRANBURY, N.J.--(BUSINESS WIRE)-- Pharmacy Times Continuing Education™ (PTCE), a leader in continuing education for oncology, health-system, specialty, managed care and retail pharmacists, will host the live video broadcast “Novel Immunotherapy Options for the Long-term Care of Patients with Chronic Lymphocytic Leukemia (CLL): The Role of Clinical and Specialty Pharmacists.” The national simulcast will take place on Tuesday, September 18, at 7 p.m. ET.

“Clinical advances in CLL have improved patient outcomes, but often involve complex treatment strategies that require collaboration between clinical and specialty pharmacists,” said Jim Palatine, RPh, MBA, president of PTCE. “We are thrilled to have the resources to present this interactive, discussion-based broadcast on the importance of integrating new and emerging CLL agents into the current treatment paradigm to enhance patient care. Clinical and specialty pharmacists need to stay up-to-date on the ever-changing landscape of CLL management, and this live broadcast will offer them a great opportunity to interact with experts on a topic of critical importance.”

Faculty presenters for the national simulcast include:

• Christopher A. Fausel, PharmD, MHA, BCOP, clinical manager, oncology pharmacy, Indiana University Health; chairman of the board, Hoosier Cancer Research Network
• Julianne Orr, PharmD, BCOP, outpatient oncology clinical pharmacist, department of pharmacy, Indiana University Health Simon Cancer Center

With the expertise of faculty, this national simulcast will illustrate current and novel treatments for CLL and highlight the importance of integrating these agents into treatment paradigms. The presenters will also discuss the role of BCR-associated kinases, such as Bruton tyrosine kinase and phosphoinositide 3-kinase, and other inhibitors of BCR signaling in CLL treatment. Additionally, participants will learn strategies to manage and counsel patients with CLL.

This activity is supported by educational grants from Pharmacyclics LLC. An AbbVie company; Janssen Biotech, Inc.; and CURE Media Group.

PTCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Attendees are eligible to earn 1.5 contact hours (0.15 CEU). For registration and more information, visit https://www.pharmacytimes.org/live/immunotherapy-options-longterm-care-cll.

About Pharmacy Times Continuing Education™

Pharmacy Times Continuing Education™ (PTCE) is a leader in continuing education for retail, health-system, managed care and specialty pharmacists. PTCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). PTCE’s print, online and live CPE activities are designed to help improve the knowledge, competence and skills of pharmacists so that they are better prepared to provide the highest quality of pharmacy care to the patients they serve and to the physicians they assist as part of a multidisciplinary treatment/management team. To learn more about the educational activities sponsored by PTCE, visit https://www.pharmacytimes.org/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180918005676/en/